Novartis (NVS) Stock Price, News & Analysis

Company Overview

Novartis International AG, traded on the New York Stock Exchange under the symbol NVS, is a global healthcare company headquartered in Basel, Switzerland. Formed in 1996 through the merger of Ciba-Geigy and Sandoz, Novartis has a rich heritage in science and innovation that spans more than 175 years. The company’s mission is to discover new ways to improve and extend people’s lives, drawing on a diverse portfolio of healthcare offerings and a commitment to research and development.

Novartis operates primarily through two major divisions: Innovative Medicines and Sandoz. Innovative Medicines focuses on patented prescription drugs across key therapeutic areas including oncology, immunology and dermatology, neuroscience, and cardiovascular and metabolic diseases. Through its Sandoz division, Novartis is a leader in generic pharmaceuticals and biosimilars, providing more affordable versions of branded medicines and expanding patient access around the world. The company also invests in advanced therapy platforms such as cell and gene therapies, aiming to address complex diseases with novel treatment modalities.

With a presence in over 140 countries, Novartis maintains a broad geographic footprint that encompasses research facilities and manufacturing sites across North America, Europe, Latin America, Asia and Africa. The company’s global reach is supported by strategic partnerships, regional research collaborations and patient access programs designed to tailor therapies to local healthcare needs. Novartis has cultivated a network of academic and industry alliances to accelerate the translation of scientific discoveries into approved medicines.

Under the leadership of Chief Executive Officer Vas Narasimhan, Novartis has emphasized digital transformation, data-driven decision-making and sustainability in its operations. The company’s senior management team brings expertise in scientific research, commercialization and global health policy, guiding a pipeline of assets that underscore Novartis’s commitment to innovation. Through disciplined portfolio management and a focus on patient-centric solutions, Novartis continues to shape the future of medicine on a worldwide scale.

Key Stats

• Today's Range: $119.98 to $122.86
• 50-Day Range: $105.18 to $123.83
• 52-Week Range: $96.06 to $124.83
• Volume: 2.75 million shs
• Average Volume: 1.58 million shs
• Market Capitalization: $255.45 billion
• P/E Ratio: 18.90
• Dividend Yield: 2.15%
• Price Target: $123.67
• Consensus Rating: Hold

Novartis Stock Analysis - MarketRank™

Novartis scored higher than 31% of companies evaluated by MarketBeat, and ranked 795th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Novartis has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 6 hold ratings, and 3 sell ratings.

Amount of Analyst Coverage

Novartis has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 4.26%

Earnings Growth

Earnings for Novartis are expected to grow by 4.26% in the coming year, from $8.45 to $8.81 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Novartis is 18.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.16.

Price to Earnings Ratio vs. Sector

The P/E ratio of Novartis is 18.90, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.28.

Price to Earnings Growth Ratio

Novartis has a PEG Ratio of 1.64. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Novartis has a P/B Ratio of 5.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.21% of the float of Novartis has been sold short.

Short Interest Ratio / Days to Cover

Novartis has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novartis has recently increased by 4.91%, indicating that investor sentiment is decreasing.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Novartis pays a meaningful dividend of 2.15%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Novartis does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Novartis is 40.63%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Novartis will have a dividend payout ratio of 29.51% next year. This indicates that Novartis will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.21% of the float of Novartis has been sold short.

Short Interest Ratio / Days to Cover

Novartis has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Novartis has recently increased by 4.91%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.92

News Sentiment

Novartis has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 25 news articles for Novartis this week, compared to 18 articles on an average week.

Search Interest

9 people have searched for NVS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Novartis insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.01% of the stock of Novartis is held by insiders.

Percentage Held by Institutions

Only 13.12% of the stock of Novartis is held by institutions.

NVS Stock Analysis - Frequently Asked Questions

How have NVS shares performed this year?

Novartis' stock was trading at $97.31 at the start of the year. Since then, NVS shares have increased by 24.3% and is now trading at $120.93.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) announced its quarterly earnings data on Tuesday, April, 29th. The company reported $2.28 EPS for the quarter, beating analysts' consensus estimates of $2.12 by $0.16. The company's revenue for the quarter was up 11.9% compared to the same quarter last year.
Read the conference call transcript.

Does Novartis have any subsidiaries?

Novartis subsidiaries include these companies: Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and more.

Who are Novartis' major shareholders?

Novartis' top institutional investors include Douglas Lane & Associates LLC (0.01%), Wealth Enhancement Advisory Services LLC (0.01%), Matthew Goff Investment Advisor LLC and Kingstone Capital Partners Texas LLC.

How do I buy shares of Novartis?

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include BlackRock (BLK), Broadcom (AVGO), UnitedHealth Group (UNH), ServiceNow (NOW), Humana (HUM), TotalEnergies (TTE) and American Water Works (AWK).

Company Calendar

• Last Earnings: 4/29/2025
• Today: 7/14/2025
• Next Earnings (Estimated): 7/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:NVS
• CIK: 1114448
• Web: www.novartis.com
• Phone: (161) 324-1111
• Fax: 41-61-324-7826
• Employees: 75,883
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Novartis: $123.67
• High Price Target: $130.00
• Low Price Target: $120.00
• Potential Upside/Downside: +2.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.40
• Trailing P/E Ratio: 18.90
• Forward P/E Ratio: 14.31
• P/E Growth: 1.64
• Net Income: $11.94 billion
• Net Margins: 24.70%
• Pretax Margin: 28.64%
• Return on Equity: 39.44%
• Return on Assets: 16.43%

Debt

• Debt-to-Equity Ratio: 0.56
• Current Ratio: 0.79
• Quick Ratio: 0.61

Sales & Book Value

• Annual Sales: $50.32 billion
• Price / Sales: 5.08
• Cash Flow: $10.69 per share
• Price / Cash Flow: 11.31
• Book Value: $21.59 per share
• Price / Book: 5.60

Miscellaneous

• Outstanding Shares: 2,112,420,000
• Free Float: 2,112,211,000
• Market Cap: $255.45 billion
• Optionable: Optionable
• Beta: 0.59